RecruitingPhase 1NCT06545331
Study of XB010 in Subjects With Solid Tumors
Sponsor: Exelixis
Austin, TX · Dallas, TX · Houston, TX · +13 more sites
Breast Cancer clinical trials in Dallas, TX
37 recruiting breast cancer studies with a site in Dallas, TX.
RecruitingEarly Phase 1NCT06008275
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
Sponsor: Baylor Research Institute
Dallas, TX
RecruitingPhase 3NCT06841354
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Sponsor: Merck Sharp & Dohme LLC
Dallas, TX · El Paso, TX · Houston, TX · +36 more sites
RecruitingPhase 3NCT07174336
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Sponsor: Eli Lilly and Company
Abilene, TX · Baytown, TX · Dallas, TX · +126 more sites
RecruitingPhase 1 / Phase 2NCT05579366
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Sponsor: Genmab
Abilene, TX · Austin, TX · Dallas, TX · +34 more sites
RecruitingPhase 1NCT07114601
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Sponsor: Eli Lilly and Company
Dallas, TX · Houston, TX · +14 more sites
RecruitingPhase 3NCT06982521
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Sponsor: Relay Therapeutics, Inc.
Austin, TX · Dallas, TX · +49 more sites
RecruitingPhase 3NCT05646862
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Sponsor: Hoffmann-La Roche
Amarillo, TX · Dallas, TX · El Paso, TX · +36 more sites
RecruitingNot applicableNCT06085833
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
Sponsor: ARTIDIS AG
Dallas, TX · Houston, TX · +1 more sites
RecruitingPhase 1 / Phase 2NCT05898399
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Sponsor: Artios Pharma Ltd
Dallas, TX · Houston, TX · +5 more sites
RecruitingPhase 3NCT06492616
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
Abilene, TX · Allen, TX · Dallas, TX · +173 more sites
RecruitingPhase not listedNCT05059444
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Sponsor: Guardant Health, Inc.
Dallas, TX · Edinburg, TX · Forth Worth, TX · +30 more sites
RecruitingPhase 2NCT06797635
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Sponsor: Merck Sharp & Dohme LLC
Dallas, TX · Houston, TX · +6 more sites
RecruitingPhase 3NCT06072612
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Sponsor: BriaCell Therapeutics Corporation
Dallas, TX · Edinburg, TX · +76 more sites
RecruitingPhase 2NCT05919108
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Sponsor: Vanderbilt-Ingram Cancer Center
Dallas, TX · Houston, TX · +3 more sites
RecruitingPhase 1NCT07182149
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Sponsor: Normunity AccelCo, Inc.
Dallas, TX · Houston, TX · San Antonio, TX · +15 more sites
RecruitingPhase 3NCT05232916
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Sponsor: Greenwich LifeSciences, Inc.
Austin, TX · Dallas, TX · +48 more sites
RecruitingPhase 3NCT05812807
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Sponsor: Alliance for Clinical Trials in Oncology
Baytown, TX · Conroe, TX · Cypress, TX · +825 more sites
RecruitingPhase 1 / Phase 2NCT06330064
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Sponsor: Daiichi Sankyo
Amarillo, TX · Dallas, TX · Pearland, TX · +15 more sites
RecruitingPhase 2NCT06695845
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Sponsor: Jazz Pharmaceuticals
Amarillo, TX · Dallas, TX · Houston, TX · +14 more sites
RecruitingPhase 1 / Phase 2NCT05768139
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Sponsor: Eli Lilly and Company
Dallas, TX · +25 more sites
RecruitingPhase 2NCT04614194
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
Sponsor: University of Texas Southwestern Medical Center
Dallas, TX
RecruitingPhase 1NCT07540572
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Sponsor: IDEAYA Biosciences
Austin, TX · Dallas, TX · Fort Worth, TX · +8 more sites
RecruitingPhase 1NCT05768932
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Sponsor: SillaJen, Inc.
Dallas, TX · Houston, TX · +8 more sites
RecruitingPhase not listedNCT03448926
The PREDICT Registry:
Sponsor: PreludeDx
Dallas, TX · Houston, TX · Plano, TX · +27 more sites
RecruitingPhase 2NCT05748834
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Sponsor: SCRI Development Innovations, LLC
Dallas, TX · San Antonio, TX · +6 more sites
RecruitingPhase 1 / Phase 2NCT06956690
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Sponsor: Hummingbird Bioscience
Dallas, TX · San Antonio, TX · +3 more sites
RecruitingPhase 2NCT06517212
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
Sponsor: Baylor Research Institute
Dallas, TX
RecruitingPhase 1 / Phase 2NCT06926920
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Sponsor: Gilead Sciences
Dallas, TX · +8 more sites
RecruitingPhase 2NCT03804944
Converting HR+ Breast Cancer Into an Individualized Vaccine
Sponsor: Weill Medical College of Cornell University
Dallas, TX · Houston, TX · +6 more sites
RecruitingPhase 4NCT04373564
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Sponsor: Guerbet
Dallas, TX · Houston, TX · +14 more sites
RecruitingPhase 2NCT05693766
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Sponsor: Sonya Reid
Dallas, TX · +2 more sites
RecruitingPhase 1 / Phase 2NCT05490472
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Sponsor: Jacobio Pharmaceuticals Co., Ltd.
Dallas, TX · +3 more sites
RecruitingPhase 1NCT06999187
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Sponsor: Dren Bio
Austin, TX · Dallas, TX · San Antonio, TX · +7 more sites
RecruitingPhase 1NCT05216432
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Sponsor: Relay Therapeutics, Inc.
Dallas, TX · Houston, TX · +22 more sites
RecruitingPhase 1NCT05746897
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
Sponsor: Hefei TG ImmunoPharma Co., Ltd.
Dallas, TX · +1 more sites
Not yet recruitingNot applicableNCT07114679
Molecular Breast Imaging (MBI)-Guided Biopsy
Sponsor: Smart Breast Corp.
Dallas, TX
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.